Market Size and Growth
The NGS-Based RNA Sequencing Market size reached USD 4.4 billion in 2025 and is estimated to reach USD 15.0 billion by 2033, growing at a CAGR of 19% during the forecast period (2026-2033). NGS-Based RNA-Sequencing is a technology used in identifying and determining the order of nucleotides in an RNA sequence.
This technique plays a vital role in analyzing transcriptomics and gene expression. NGS-Based RNA-Sequencing is a faster and more reliable technology to obtain genetic information from samples, and at a lower cost than ever before with a significant increase in throughput capabilities.
Market Scope
| Metrics | Details |
| Market CAGR | 19% |
| Segments Covered | By Product & Services, By Technology, By Application, By End-user, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Know More Insights: Download Sample
Market Dynamics and Trends
The global NGS based RNA Sequencing Market growth is driven by the surge in the number of product approvals for RNA-sequencing platforms and consumables, advancements in data analysis & storage, automation in sample generation techniques, as well as augmenting genomic research in the fields of rare genetic diseases and autoimmune diseases are leading to growth in adoption of NGS-based RNA-Sequencing products.
Advantages of RNA-sequencing over the conventional technologies is expected to drive the growth in the forecast period
NGS-based RNA-sequencing offers several advantages over the conventional methods for transcriptome analysis with cost-effective procedures. Since it allows direct quantification and identification of transcripts, it is becoming a de facto standard approach for investigating and optimizing mammalian cells. In addition, NGS-based RNA-sequencing eliminates non-ideal hybridization and cross-hybridization, as observed in microarrays. This technique provides absolute values with higher specificity and can quantify the large dynamic range of expression levels. Since NGS-based RNA-sequencing allows the detection of novel transcripts, this technology is emerging as an alternative to whole-genome transcriptome profiling. Therefore, as mentioned above, these factors are collectively responsible for the growth of the NGS based RNA Sequencing Market over the analysis period.
Instability of RNA under normal conditions are likely to hinder the market growth
The instability of RNA under normal conditions and lack of standardization are expected to hinder the market growth in the coming years.
Market Segment Analysis
The RNA sequencing platform & consumables segment is expected to hold the largest share in this market segment
The RNA sequencing platform & consumables segment is projected to hold the largest market share throughout the forecast period. This growth is majorly attributed to the availability of innovative RNA sequencing platforms provided by key market players. Some of these platforms include Illumina HiSeq, SOLiD systems, Oxford Nanopore Technologies (ONT) Nanopore sequencing, Ion Torrent, and PacBio IsoSeq, among others. These platforms have revolutionized the study of transcriptome by providing researchers the perceptibility to acknowledge the changes in the diseased state of an individual that previously went undetected. RNA sequencing platform & consumables allow measuring transcriptome expression by detecting gene fusions, transcript isoforms, and single nucleotide variants. Moreover, technological advancements in the field of next-generation sequencing techniques and continuous R&D efforts of biotechnological companies for manufacturing cost-effective and innovative RNA sequencing platforms for cancer research are also boosting the market growth over the forecast period. Technological advancements such as RNA interference (RNAi) improve accuracy and precision, thereby, assisting researchers in analyzing the transcriptional activity. For instance, NGS tools manufactured by Illumina, Inc., are highly successful in fragmenting RNA into several pieces, sequencing the libraries, adding adapters, and reassembling them to form a genomic sequence.
Market Geographical Share
North America region holds the largest market share of global NGS based RNA Sequencing Market
Within North America, the United States has held the major share of the market and is expected to dominate over the forecast period. The presence of major biotechnological research companies such as Illumina, Inc., Thermo Fischer Scientific Inc., Agilent Technologies, Inc., PerkinElmer Inc., and GENEWIZ, Inc. in the region coupled with the early adoption of NGS technology contribute toward the growth of the market. Upsurge in funding from the private players and federal government, as well as the increased implementation of RNA sequencing technologies by non-government and government bodies for biomedical and genomic research purposes, is anticipated to enhance the adoption of NGS-based RNA-sequencing techniques, majorly in the United States. Likewise, the increasing prevalence of systemic autoimmune and oncologic diseases together with progressions in gene expression analysis and regulation studies are likely to drive the growth of the NGS based RNA Sequencing Market in North America. For instance, systemic autoimmune disease such as rheumatoid arthritis is one of the most common autoimmune disorders and has affected over 1.3 million Americans in 2018, as per Rheumatoid Arthritis Organization.
Recent Developments
April 2026: Strategic collaborations for multi-omics integration
Leading genomics firms entered partnerships with healthcare and pharma companies to integrate RNA sequencing with proteomics and genomics platforms, enabling comprehensive multi-omics analysis for drug discovery and disease mechanism studies.
March 2026: Rising adoption in clinical diagnostics and precision medicine
Hospitals and diagnostic labs expanded the use of NGS-based RNA sequencing for clinical applications, particularly in infectious disease profiling and personalized oncology treatment selection. This reflects a shift from research-only usage toward routine clinical deployment.
February 2026: AI-integrated RNA sequencing data analysis tools launched
Bioinformatics companies introduced AI-powered RNA-seq analysis platforms that automate differential gene expression, splice variant detection, and biomarker discovery. This development is reducing turnaround time and improving accuracy in clinical research pipelines.
January 2026: Expansion of single-cell RNA sequencing platforms
Major sequencing solution providers accelerated the rollout of next-generation single-cell RNA-seq workflows, improving resolution for immune profiling and oncology research. This trend is driven by increasing demand for high-precision transcriptomic mapping in cancer and rare disease studies.
Market Companies and Competitive Landscape
The global NGS based RNA Sequencing Market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Illumina, Inc., Oxford Nanopore Technologies, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., PerkinElmer, Inc., F. Hoffmann-La Roche Ltd, Hamilton Company, and Takara Bio Inc. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market. For instance, In May 2021, Bio-Rad Laboratories, Inc. launched SEQuoia RiboDepletion Kit for NGS that eliminates irrelevant ribosomal RNA from the RNA-sequencing library and improves assay efficiency.
NGS based RNA Sequencing Market – Key Companies to Watch
Agilent Technologies, Inc
Overview: Agilent Technologies Inc is a global leader in life sciences, diagnostics and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions and people provide trusted answers to customers' most challenging questions. The company generated revenues of $4.91 billion in fiscal 2018 and employs 15,550 people worldwide.
Product Portfolio: It includes product like SureSelect Strand-Specific RNA Library Preparation kit prepares Poly(A) enriched libraries for whole-transcriptome sequencing. Sequence a wide range of RNA to detect gene expression changes and alternative splicing. The kit contains mRNA sequencing library preparation and enrichment materials.
